Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Stimolazione Magnetica Transcranica Ripetitiva (rTMS) Periodica ad Alta Intensità e Bassa Frequenza sulla Corteccia Prefrontale Dorsolaterale Destra per la Regolazione Autonomica Cardiaca in Donne con Aborti Ricorrenti e Ansia

1 novembre 2026 aggiornato da: Lin Tao, Shenyang Medical College

Effetti della Stimolazione Magnetica Transcranica (rTMS) Periodica ad Alta Intensità e Bassa Frequenza sulla Corteccia Prefrontale Dorsolaterale Destra sulla Regolazione Autonoma Cardiaca in Donne con Aborto Ricorrente e Ansia: Uno Studio Randomizzato, Controllato con Sham, di Prova di Concetto (NEURO-CARD-rTMS-2)

The goal of this clinical trial is to determine whether high-intensity, low-frequency periodic repetitive transcranial magnetic stimulation (rTMS) applied to the right dorsolateral prefrontal cortex (DLPFC) can modulate cardiac autonomic regulation in women with recurrent pregnancy loss (RPL) and comorbid anxiety. The main questions it aims to answer are:

Does 120% resting motor threshold (RMT) rhythmic low-frequency rTMS reduce heart rate during stimulation time windows compared with sham stimulation?

Does 120% RMT rTMS alter heart-rate-variability (HRV) spectral power at the target frequency (0.0167 Hz) compared with sham stimulation?

Researchers will compare active rTMS with sham rTMS to determine whether the active intervention produces measurable changes in cardiac autonomic activity.

Participants will:

Undergo a single session of rTMS or sham stimulation consisting of 20 consecutive stimulation time windows (each 60 seconds: 40 seconds of 1-Hz stimulation plus 20 seconds of rest) targeting the right DLPFC;

Have continuous electrocardiography (ECG) recordings collected during the entire stimulation session;

Complete clinical and psychiatric assessments before participation.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

For this protocol, recurrent pregnancy loss (RPL) was defined as two or more consecutive spontaneous miscarriages before 28 weeks of gestation. RPL affects approximately 2-5% of reproductive-age couples worldwide and imposes a substantial clinical and emotional burden. Beyond its implications for reproductive health, RPL is increasingly recognized as a condition associated with systemic consequences, including heightened anxiety, altered autonomic nervous system function, and increased long-term cardiovascular risk.

Emerging evidence suggests that in women with RPL and comorbid anxiety, chronic psychological stress may lead to dysregulation of the autonomic nervous system, characterized by increased sympathetic tone, reduced vagal activity, elevated resting heart rate, and decreased heart rate variability (HRV). These alterations may create a maladaptive feedback loop that reinforces emotional distress, autonomic imbalance, and reproductive vulnerability.

To address this issue, this randomized, sham-controlled, proof-of-concept clinical trial will investigate whether low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the right dorsolateral prefrontal cortex (DLPFC)-a region critically involved in emotion regulation and autonomic control-can modulate cardiac autonomic function in women with RPL and anxiety.

The intervention protocol is based on findings from a prior dose-finding study (NEURO-CARD-rTMS-1), which indicated that stimulation at 120% of resting motor threshold (RMT) produced significant reductions in heart rate without compromising tolerability. Building on this, the current trial (NEURO-CARD-rTMS-2) will apply 1-Hz rhythmic rTMS at 120% RMT over the right DLPFC, delivered in 20 consecutive stimulation windows (each 60 seconds long: 40 seconds of stimulation followed by 20 seconds of rest). This stimulation paradigm aligns with the very-low-frequency (VLF) band of HRV (~0.0167 Hz), enabling frequency-specific entrainment analysis.

The primary endpoint will be the difference in baseline-corrected mean heart rate during the stimulation time windows between the active and sham groups. Secondary endpoints include changes in HRV spectral power at 0.0167 Hz and brain-heart coupling (BHC), defined as the correlation between heart rate and spectral power at this frequency. Safety outcomes will be monitored throughout the procedure.

All electrocardiographic (ECG) data will be recorded continuously at 1000 Hz using a wireless Bluetooth system. Participants will undergo standardized psychiatric assessments based on DSM-5 criteria, and key demographic and clinical variables (e.g., BMI, blood pressure, medication use, number and cause of miscarriages) will be collected for covariate analysis.

This trial aims to provide initial mechanistic evidence for the feasibility and physiological efficacy of right DLPFC-targeted neuromodulation in improving autonomic regulation in a high-risk, psychologically sensitive population. If successful, the findings will support the development of non-invasive, brain-based interventions to improve both reproductive and cardiovascular outcomes in women with RPL and anxiety.

Tipo di studio

Interventistico

Iscrizione (Stimato)

48

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Liaoning
      • Shenyang, Liaoning, Cina, 110001
        • Reclutamento
        • The Second Affiliated Hospital of Shenyang Medical College
        • Contatto:
      • Shenyang, Liaoning, Cina, 110024
        • Reclutamento
        • Central Hospital Affiliated to Shenyang Medical College
        • Contatto:
      • Shenyang, Liaoning, Cina, 110086
        • Reclutamento
        • 242 Hospital Affiliated to Shenyang Medical College
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 45 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • (i) Female, aged 18-45 years, and right-handed;
  • (ii) Diagnosed with recurrent pregnancy loss (RPL), defined as two or more consecutive spontaneous miscarriages occurring before 28 weeks of gestation;
  • (iii) Not currently pregnant or in a state of missed miscarriage;
  • (iv) Meeting the DSM-5 diagnostic criteria for GAD, with a HAMA score of at least 16, a CGI-S score of at least 4, and a HAMD-17 score of no more than 17.

Exclusion Criteria:

  • (i) Contraindications to transcranial magnetic stimulation (TMS), such as metallic implants or a history of epilepsy;
  • (ii) Unstable blood pressure (systolic >180 mmHg or <90 mmHg);
  • (iii) Coexisting major organic disorders, including hyperthyroidism, atrial fibrillation, valvular heart disease, sinus bradycardia, neurological diseases, cerebrovascular disease, or pulmonary disorders;
  • (iv) Significant suicide risk;
  • (v) Other current major psychiatric disorders, including substance use disorder, schizophrenia, delusional disorder, unspecified psychotic disorder, bipolar disorder, or delirium. To preserve diagnostic homogeneity of the study sample, participants whose current primary diagnosis is another anxiety-related disorder will also be excluded, including panic disorder, social anxiety disorder, separation anxiety disorder, specific phobia, obsessive-compulsive and related disorders, and trauma- and stressor-related disorders; Current use of psychotropic medication at screening, or continuous use within the 4 weeks before screening of antidepressants, anxiolytics, antipsychotics, mood stabilizers, or sedative-hypnotics, in order to minimize hemodynamic confounding.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: real rTMS group

Participants in this arm will receive active repetitive transcranial magnetic stimulation (rTMS) delivered to the right dorsolateral prefrontal cortex (DLPFC). In Stage 1, the stimulation protocol consists of 20 consecutive cycles of low-frequency (1 Hz) rTMS at 120% of the resting motor threshold (RMT), with each cycle comprising 40 seconds of stimulation followed by 20 seconds of rest. The total stimulation duration is approximately 20 minutes. Real stimulation is applied with the figure-of-eight coil positioned tangentially to the scalp. After completion of Stage 1 and the post-procedure safety observation period, participants may voluntarily enter a prespecified exploratory Stage 2 subgroup for 4 weeks of continued treatment and follow-up while remaining in their original randomized assignment. Participants who enter Stage 2 will continue to receive active stimulation under the same fixed-parameter framework; no re-randomization will be performed.

Participants assigned to the active rTMS group will receive rhythmic low-frequency repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex (DLPFC). In Stage 1, the intervention consists of 20 consecutive stimulation cycles, each comprising 40 seconds of 1 Hz stimulation followed by a 20-second inter-cycle interval, for a total of 60 seconds per cycle. The stimulation intensity is set at 120% of the individual resting motor threshold (RMT). A figure-of-eight coil will be positioned tangentially over the scalp at the targeted right DLPFC site. Electrocardiogram (ECG) signals will be recorded continuously throughout the session. After completion of the acute Stage 1 procedure and the post-procedure safety observation period, participants may voluntarily enter a prespecified exploratory Stage 2 subgroup for 4 weeks of continued treatment and follow-up while remaining in their original randomized assignment. Participants who enter Stage 2 will cont

Comparatore fittizio: sham rTMS group

Participants in this arm will receive sham repetitive transcranial magnetic stimulation (rTMS) over the right dorsolateral prefrontal cortex (DLPFC). In Stage 1, the stimulation protocol mimics the active condition in timing and coil placement but involves tilting the coil at a 45-degree angle to the scalp, significantly attenuating magnetic field penetration. This approach preserves the auditory and tactile sensations of stimulation without producing cortical effects. The procedure consists of 20 consecutive cycles of sham stimulation, each comprising 40 seconds of simulated stimulation followed by 20 seconds of rest, lasting approximately 20 minutes in total. After completion of Stage 1 and the post-procedure safety observation period, participants may voluntarily enter a prespecified exploratory Stage 2 subgroup for 4 weeks of continued treatment and follow-up while remaining in their original randomized assignment. Participants who enter Stage 2 will continue to receive sham stimu

Participants assigned to the sham rTMS group will receive sham rhythmic low-frequency repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex (DLPFC). In Stage 1, the sham procedure matches the active condition in timing, coil position, and auditory and tactile experience, with 20 consecutive sham stimulation cycles, each comprising 40 seconds of simulated stimulation followed by a 20-second inter-cycle interval, for a total of 60 seconds per cycle. The coil will be held at a 45-degree angle to the scalp to minimize effective cortical stimulation while preserving the sensory characteristics of the procedure. Electrocardiogram (ECG) signals will be recorded continuously throughout the session. After completion of the acute Stage 1 procedure and the post-procedure safety observation period, participants may voluntarily enter a prespecified exploratory Stage 2 subgroup for 4 weeks of continued treatment and follow-up while remaining in their original ran

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The primary endpoint will be the between-group difference in baseline-corrected mean heart rate, averaged across stimulation time windows.
Lasso di tempo: Session 1 (Day 1)

Heart rate (HR) will be continuously recorded via ECG (1,000 Hz) during a single rTMS session comprising 20 stimulation cycles (each 60 s: 40 s stimulation at 1 Hz, then 20 s rest). For each cycle, a 50-s analysis window will be defined (-10 s to 0 s pre-stimulation baseline; 0 s to +40 s post-stimulation). Baseline-corrected mean HR for each cycle will be computed as the mean HR in the post-stimulation segment (0-40 s) minus the mean HR in the 10-s pre-stimulation baseline (-10-0 s). Per-participant values will then be averaged across the 20 stimulation time windows, and the primary endpoint will compare these averaged baseline-corrected means between the active and sham rTMS groups.

Session 1 (Day 1)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The between-group difference in heart rate variability (HRV) spectral power at the target frequency (0.0167 Hz), averaged across stimulation time windows.
Lasso di tempo: Session 1 (Day 1)

HRV spectral power at the target frequency will be derived from R-R interval (RRI) series obtained from continuous ECG recorded at 1,000 Hz. Following resampling, linear detrending, and band-pass filtering, the RRI series will undergo wavelet-based time-frequency analysis. For each stimulation cycle, mean wavelet power within the target frequency band will be quantified over the corresponding analysis window. Window-level estimates will then be averaged across the 20 cycles to obtain a participant-level summary measure, which will be compared between the active and sham groups.

Session 1 (Day 1)
The strength of the linear correlation between baseline-corrected mean heart rate and spectral power at 0.0167 Hz, averaged across stimulation time windows, in the active rTMS group.
Lasso di tempo: Session 1 (Day 1)

For each participant in the active rTMS group, the linear correlation (Pearson's r) between these two window-wise measures will be calculated across the 20 stimulation time windows.

Session 1 (Day 1)
The strength of the linear correlation between baseline-corrected mean heart rate and spectral power at 0.0167 Hz, averaged across stimulation time windows, in the sham rTMS group.
Lasso di tempo: Session 1 (Day 1)

For each participant in the sham rTMS group, the linear correlation (Pearson's r) between these two window-wise measures will be calculated across the 20 stimulation time windows.

Session 1 (Day 1)
Incidence of mild adverse events during rTMS stimulation, including scalp discomfort at the stimulation site, facial muscle twitching, mild headache, and dizziness.
Lasso di tempo: Session 1 (Day 1)

This outcome will capture the incidence (proportion of participants with ≥1 event) of prespecified mild adverse events during the rTMS session and the immediate 1-hour post-session observation period. Mild events include scalp discomfort at the stimulation site, facial muscle twitching, mild headache, and dizziness. Events will be solicited and recorded in real time by trained operators using a standardized checklist, with participant self-report. Vital signs (blood pressure and resting heart rate) will be reassessed at the end of the session. Events will be classified as mild if transient, self-limited, not requiring medical treatment, and not meeting serious adverse event criteria (e.g., syncope or seizure). Incidence will be summarized by group (active vs sham) for comparison.

Session 1 (Day 1)
Incidence of serious adverse events during rTMS stimulation, including syncope and seizures.
Lasso di tempo: Session 1 (Day 1)

This outcome will quantify the incidence (proportion of participants with ≥1 event) of serious adverse events (SAEs) occurring during the rTMS session and the subsequent 1-hour observation period. SAEs will be defined per ICH-GCP criteria (events that are fatal, life-threatening, require inpatient hospitalization or prolong an existing hospitalization, result in persistent or significant disability/incapacity, or are otherwise medically important). Events of special interest include syncope and seizures. Trained operators will actively monitor and document SAEs in real time using standardized case-report forms, including onset time, duration, actions taken, outcome, and relatedness to the intervention. Any suspected SAE will trigger protocol-specified safety procedures (immediate termination of stimulation, vital-sign reassessment, medical evaluation, and referral as needed). Incidence will be summarized by group (active vs sham).

Session 1 (Day 1)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Hamilton Anxiety Rating Scale (HAMA) score from baseline
Lasso di tempo: Baseline; treatment Week 3; end of treatment at Week 4; 1 month, 3 months, and 6 months after treatment.

In the prespecified exploratory Stage 2 subgroup, change in HAMA total score from baseline will be assessed at treatment Week 3, at the end of treatment (Week 4), and at 1 month, 3 months, and 6 months after treatment. The HAMA total score ranges from 0 to 56, with higher scores indicating greater anxiety severity.

Baseline; treatment Week 3; end of treatment at Week 4; 1 month, 3 months, and 6 months after treatment.
Clinical Global Impression-Improvement (CGI-I) scores and change in 17-item Hamilton Depression Rating Scale (HAMD-17) scores from baseline
Lasso di tempo: Baseline; treatment Week 3; end of treatment at Week 4; 1 month, 3 months, and 6 months after treatment.

In the prespecified exploratory Stage 2 subgroup, CGI-I and HAMD-17 will be assessed at treatment Week 3, at the end of treatment (Week 4), and at 1 month, 3 months, and 6 months after treatment. CGI-S will be assessed at baseline only. CGI-I is a postbaseline rating of overall improvement relative to baseline. The CGI-I score ranges from 1 to 7, with lower scores indicating greater improvement. The HAMD-17 total score ranges from 0 to 52, with higher scores indicating greater depressive symptom severity.

Baseline; treatment Week 3; end of treatment at Week 4; 1 month, 3 months, and 6 months after treatment.
Response and remission rates at each assessment time point
Lasso di tempo: Treatment Week 3; end of treatment at Week 4; 1 month, 3 months, and 6 months after treatment.

In the prespecified exploratory Stage 2 subgroup, response and remission rates will be calculated separately by group at treatment Week 3, at the end of treatment (Week 4), and at 1 month, 3 months, and 6 months after treatment. Response will be defined as a reduction of at least 50% in HAMA score from baseline. Remission will be defined as HAMA <8 together with a CGI-I score of 1 or 2. Between-group differences between the active stimulation group and the sham stimulation group will be evaluated at each time point.

Treatment Week 3; end of treatment at Week 4; 1 month, 3 months, and 6 months after treatment.
Exploratory mediation analyses linking the acute physiological response during the first session to subsequent change in HAMA score
Lasso di tempo: First acute session on Day 1; end of treatment at Week 4; 1 month after treatment; 3 months after treatment.

Exploratory mediation analyses will use group as the independent variable, the magnitude of baseline-corrected heart rate deceleration during the first acute session as the mediator, and the change in HAMA score at the end of treatment, 1 month after treatment, and 3 months after treatment as separate dependent variables. The HAMA total score ranges from 0 to 56, with higher scores indicating greater anxiety severity. These analyses are intended to evaluate whether the acute physiological response during the first session may mediate subsequent improvement in anxiety symptoms. Results will be used for mechanistic hypothesis generation and will not be interpreted as confirmatory.

First acute session on Day 1; end of treatment at Week 4; 1 month after treatment; 3 months after treatment.
Participants' subjective judgment of treatment assignment for assessment of blinding performance
Lasso di tempo: 3 months after treatment.

Blinding assessment will be conducted at the 3-month follow-up visit after treatment in the prespecified exploratory Stage 2 subgroup. Participants will be asked for their subjective judgment of treatment assignment using a 5-point scale: 0, definitely not in the active group; 1, inclined to think not in the active group; 2, unable to judge; 3, inclined to think in the active group; and 4, very certain of being in the active group. These results will be described by group, and group differences in distribution will also be compared.

3 months after treatment.
Safety outcomes in the exploratory Stage 2 subgroup receiving 4 weeks of continuous treatment
Lasso di tempo: During the 4-week treatment period; within 30 days after the final treatment session; and at the 3-month and 6-month follow-up visits after treatment.

Safety outcomes will include adverse events and serious adverse events occurring during the 4-week treatment period and within 30 days after the final treatment session, together with unresolved adverse events, hospitalization, unintended pregnancy, significant worsening of psychiatric symptoms, and major changes in concomitant treatment at the 3-month and 6-month follow-up visits after treatment. Safety outcomes will be summarized by group and compared between the active stimulation group and the sham stimulation group. No numerical symptom scale applies to this outcome.

During the 4-week treatment period; within 30 days after the final treatment session; and at the 3-month and 6-month follow-up visits after treatment.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Cattedra di studio: Yun-En Liu, MD, Shenyang Medical College
  • Investigatore principale: Lin Tao, MM, Shenyang Medical College
  • Direttore dello studio: Fei Meng, MD, Central Hospital Affiliated to Shenyang Medical Collage

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 novembre 2025

Completamento primario (Effettivo)

22 giugno 2026

Completamento dello studio (Stimato)

12 gennaio 2027

Date di iscrizione allo studio

Primo inviato

14 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

14 novembre 2025

Primo Inserito (Effettivo)

18 novembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 novembre 2026

Ultimo verificato

1 dicembre 2025

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2025-038-02_V2

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data, study protocol and supporting materials will be made publicly available at the time of formal publication. Data will be hosted on an internationally recognised third-party repository and accessible for non-commercial scientific use.

Periodo di condivisione IPD

Available at the time of formal publication

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .